Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol at impasse with ADAPs

Executive Summary

Negotiations between Bristol-Myers Squibb and coalition of state AIDS Drug Assistance Program directors has "stalled," Treatment Action Group Representative Robert Camp says during Bristol Reyataz advisory committee meeting. "I am here to express profound disappointment at BMS' failure to negotiate serious price discounts and freezes in good faith with state and territorial ADAP directors." Bristol is one of three HIV therapy manufacturers who has not yet reached an agreement with the state AIDS program; other companies include Pfizer/Agouron and GlaxoSmithKline (1"The Pink Sheet" April 28, In Brief)...

You may also be interested in...



ADAP/manufacturer agreements

Pfizer, GlaxoSmithKline and Boehringer-Ingelheim agree to provide additional aid to AIDS Drug Assistance Programs. GSK will offer a "$20 mil. financial aid package" to ADAPs to help cut waiting lists and avoid program restrictions, company says. Pfizer is offering its antiretroviral drugs Viracept and Rescriptor "either free or at greatly discounted prices" and will "maintain price neutrality" on its new 625 mg Viracept formulation compared to older formulations, Pfizer says. Negotiations with Bristol-Myers Squibb continue (1"The Pink Sheet" May 19, 2003, In Brief)...

State ADAPs secure higher Rx discounts

Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

UsernamePublicRestriction

Register

PS041803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel